Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

As well as triggering weight loss – a result of the active ingredient semaglutide making ... drug and bariatric surgery patients. Additionally, those taking the injection were less likely ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, but growth may accelerate after 2026. Read more here.

Ozempic (semaglutide) is a brand-name drug prescribed ... Ozempic is a solution for subcutaneous injection that’s approved by the Food and Drug Administration (FDA) to: An interaction occurs ...

Higher-dose weight loss injections now available ... demonstrated remarkable outcomes for patients using the higher-dose semaglutide. Participants experienced an average of 20.7% total body ...

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital ...